Bucking trends.
Backed by experience. 

For more than a decade, Dr. Travis Stiles has exclusively studied the mechanisms underlying regenerative failure in the CNS. His work led to the discovery of a novel therapeutic target for the promotion of neuronal tissue regeneration after CNS damage and disease. To best translate his work into viable therapies, Dr. Stiles co-founded Novoron Bioscience early in 2014.

Dr. Stiles earned a PhD in Biomedical Science from the University of California, San Diego (UCSD), an MA in Exercise Physiology from the University of the Pacific, and a BA in Exercise Science from Willamette University. He has been recognized as a top innovator by groups such as J&J and Biocom and has been awarded over $3 million in federal grants. In addition, Dr. Stiles has served on multiple scientific review boards for the National Institute of Health and recently completed a four-year Federal Advisory Committee appointment to the Scientific Merit Review Board subcommittee for Regenerative Medicine in the Department of Veterans Affairs.

Mr. Drummond has more than 15 years experience working in the medical research sector. Initially, he worked as a laboratory scientist at The University of Melbourne, investigating the role of post-translational modifications to myelin antigens as a potential cause of multiple sclerosis.

In 2012, Mr. Drummond co-founded MStranslate - a science communication initiative designed to provide accurate and easy to understand updates on the latest in multiple sclerosis research to the MS community. His work in this area has been recognised worldwide, also leading him to be selected as the host of the official European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS) podcast series.

Johanna has a background in Biochemistry and Molecular biology, studying at the University of Melbourne, and experience working within the pharmaceutical industry. Throughout her time at GSK in the Vaccines Medical team, Johanna's experiences included establishing a cross-functional project management system across 8 streams in a pre-registration environment, facilitation of collaborations from a variety of team members across numerous disease areas/functions/roles to establish a unified approach to getting ahead of disease together and leading the external relationship management for numerous third-party partnerships.

In her role as Program Manager & Strategy Lead, Johanna builds on her prior experience to lead the management of any Australian research collaborations and programs, develop new relationships with various stakeholders across Australia and build Novoron's presence in Australia. The goal being to accelerate the development of novel therapeutics that could benefit the lives of numerous Australians.

After completing her PhD at Monash University, Dr. Bye has spent more than 20 years contributing to neuroscience research. Her post-doctoral appointments, undertaken at Monash University, The Alfred Hospital and The University of Melbourne, involved investigating the mechanisms of pathology and regenerative pathways in traumatic brain injury.

Dr. Bye has authored more than 20 peer-reviewed publications on her research and 4 book chapters. Her excellent work was recognised by being awarded an early-career research fellowship from the Victorian Neurotrauma Initiative.

Dr Dave Gell is a protein scientist with close to three decades of research experience at the bench. Hailing from Liverpool and Yorkshire in the UK, he completed his PhD in protein biochemistry at the University of Cambridge, then spent ten years training in structural biology (protein NMR and x-ray crystallography) as a postdoctoral fellow at the University of Sydney.

Dave then set up a research group at the University of Tasmania, where he now holds an adjunct position. His research has been supported by fellowships and research grants from the Wellcome Trust (UK), the ARC and the NHMRC. He has enjoyed collaborations with groups in Australia, Europe and the US to make meaningful contributions in many areas of biology, including neuroscience, cancer, red blood cell production and host-microbe interactions. This work has received over 3400 citations (Web of Science) and includes publications in high-profile journals such as Cell, Nature and the Journal of Clinical Investigation.